Pathogenic bacteria binding sites on intestinal epithelium

Pathogenic bacteria binding sites on the intestinal epithelium are a heterogeneous group of host molecules, including glycoproteins, glycolipids, and integrins, that serve as anchors for bacterial attachment (Barnich et al., 2007). These sites are essential for the colonization and virulence of enteric pathogens such as Adherent-Invasive Escherichia coli (AIEC), Salmonella, and Shigella, which use specialized surface proteins called adhesins to recognize specific host motifs (Klemm et al., 2010). In conditions like Crohn's disease, the over-expression of these receptors, such as CEACAM6, facilitates persistent bacterial colonization and subsequent chronic inflammation (Spaeth et al., 2013). Therapeutic targeting of these sites, often referred to as anti-adhesion therapy, utilizes small molecules or carbohydrate decoys to block the interaction between bacterial adhesins and host receptors. For example, the drug Sibofimloc (EB8018) is designed to inhibit the FimH adhesin from binding to mannosylated receptors on the gut lining (Enterome, 2023). This approach offers a non-antibiotic alternative that potentially reduces the risk of developing antimicrobial resistance while maintaining the integrity of the commensal microbiota. Other agents like human milk oligosaccharides (HMOs) act as decoy receptors, mimicking these binding sites to divert pathogens away from the epithelium (Bode, 2012). Overall, these binding sites represent a critical interface for host-pathogen interactions and a promising avenue for treating gastrointestinal infections and inflammatory disorders.

Competitive inhibition of bacterial adhesins (e.g., FimH) to host epithelial receptors (e.g., CEACAM6 or mannosylated glycoproteins), preventing bacterial colonization and subsequent inflammatory cascades.